0.630
-0.03 (-4.40%)
| Previous Close | 0.659 |
| Open | 0.660 |
| Volume | 50,607 |
| Avg. Volume (3M) | 312,562 |
| Market Cap | 19,565,406 |
| Price / Book | 2.53 |
| 52 Weeks Range | |
| Earnings Date | 10 Aug 2023 - 14 Aug 2023 |
| Diluted EPS (TTM) | -0.580 |
| Total Debt/Equity (MRQ) | 0.09% |
| Current Ratio (MRQ) | 11.01 |
| Operating Cash Flow (TTM) | -19.38 M |
| Levered Free Cash Flow (TTM) | -10.27 M |
| Return on Assets (TTM) | -46.95% |
| Return on Equity (TTM) | -79.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Inhibikase Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.38 |
|
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (PD), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.02% |
| % Held by Institutions | 74.49% |
| 52 Weeks Range | ||
| Median | 4.00 (534.92%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 11 Dec 2025 | 4.00 (534.92%) | Buy | 1.50 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |